Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses

OncoImmunology

Volumn 5, Issue 11, 2016, Pages

  Hotz, Christian ^a   Treinies, Marina ^a   Mottas, Ines ^a,b   Rötzer, Laurin C ^c   Oberson, Anne ^a   Spagnuolo, Lorenzo ^a   Perdicchio, Maurizio ^a   Spinetti, Thibaud ^a   Herbst, Tina ^a   Bourquin, Carole ^a,b  

^a University of Fribourg   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cancer immunotherapy; dendritic cells; poly(I:C); RIG I like receptors agonists; Toll like receptors

Indexed keywords

CD40 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; INTERLEUKIN 12P70; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY ASSAY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTRACELLULAR SIGNALING; NATURAL KILLER CELL; NONHUMAN; NUCLEAR REPROGRAMMING; PHENOTYPE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; TH1 CELL; TUMOR IMMUNITY; UPREGULATION; WESTERN BLOTTING;

EID: 84994158598     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1232219     Document Type: Article

References (45)

1. Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance:new approaches to an old challenge. Cancer Res 2015; 75:5-10; PMID:25524899; doi:10.1158/0008-5472.CAN-14-2538
2. Steinman RM, Hemmi H. Dendritic cells:translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311:17-58; PMID:17048704; doi:10.1007/3-540-32636-7_2
3. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 2007; 26:503-17; PMID:17398124; doi:10.1016/j.immuni.2007.03.006
4. Junt T, Barchet W. Translating nucleic acid-sensing pathways into therapies. Nat Rev Immunol 2015; 15:529-44; PMID:26292638; doi:10.1038/nri3875
5. Peris K, Campione E, Micantonio T, Marulli GC, Fargnoli MC, Chimenti S. Imiquimod treatment of superficial and nodular basal cell carcinoma:12-week open-label trial. Dermatol Surg Off Publ Am Soc Dermatol Surg Al 2005; 31:318-23; PMID:15841634
6. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, Ding L, Thissen MRTM. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma:randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 2002; 147:1227-36; PMID:12452875; doi:10.1046/j.1365-2133.2002.05069.x
7. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch. Oncoimmunology 2012; 1:699-716; PMID:22934262; doi:10.4161/onci.20696
8. Duewell P, Beller E, Kirchleitner SV, Adunka T, Bourhis H, Siveke J, Mayr D, Kobold S, Endres S, Schnurr M. Targeted activation of melanoma differentiation-associated protein 5 (MDA5) for immunotherapy of pancreatic carcinoma. Oncoimmunology 2015; 4:e1029698; PMID:26504669; doi:10.1080/2162402X.2015.1029698
9. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, Kirschnek S, Gaffal E, Landsberg J, Hellmuth J, et al. 5′-Triphosphate-siRNA:turning gene silencing and Rig-I activation against melanoma. Nat Med 2008; 14:1256-63; PMID:18978796; doi:10.1038/nm.1887
10. Loo Y-M, Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011; 34:680-92; PMID:21616437; doi:10.1016/j.immuni.2011.05.003
11. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity 2010; 32:305-15; PMID:20346772; doi:10.1016/j.immuni.2010.03.012
12. Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011; 34:637-50; PMID:21616434; doi:10.1016/j.immuni.2011.05.006
13. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413:732-8; PMID:11607032; doi:10.1038/35099560
14. Gitlin L, Benoit L, Song C, Cella M, Gilfillan S, Holtzman MJ, Colonna M. Melanoma differentiation-associated gene 5 (MDA5) is involved in the innate immune response to Paramyxoviridae infection in vivo. PLoS Pathog 2010; 6:e1000734; PMID:20107606; doi:10.1371/journal.ppat.1000734
15. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1–polarizing program in dendritic cells. Nat Immunol 2005; 6:769-76; PMID:15995707; doi:10.1038/ni1223
16. Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, Kulig P, Becher B. New insights into IL-12-mediated tumor suppression. Cell Death Differ 2015; 22:237-46; PMID:25190142; doi:10.1038/cdd.2014.134
17. Hotz C, Roetzer LC, Huber T, Sailer A, Oberson A, Treinies M, Heidegger S, Herbst T, Endres S, Bourquin C. TLR and RLR signaling are reprogrammed in opposite directions after detection of viral infection. J Immunol Baltim Md 1950 2015; 195:4387-95; PMID:26392465; doi:10.4049/jimmunol.1500079
18. Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, Storch B, Sandholzer N, Wurzenberger C, Anz D, et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res 2011; 71:5123-33; PMID:21697281; doi:10.1158/0008-5472.CAN-10-3903
19. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003; 3:133-46; PMID:12563297; doi:10.1038/nri1001
20. Gagnon J, Ramanathan S, Leblanc C, Cloutier A, McDonald PP, Ilangumaran S. IL-6, in synergy with IL-7 or IL-15, stimulates TCR-independent proliferation and functional differentiation of CD8+ T lymphocytes. J Immunol Baltim Md 1950 2008; 180:7958-68; PMID:18523259; doi:10.4049/jimmunol.180.12.7958
21. Heidegger S, Kirchner S-K, Stephan N, Bohn B, Suhartha N, Hotz C, Anz D, Sandholzer N, Stecher B, Rüssmann H, et al. TLR activation excludes circulating naive CD8+ T cells from gut-associated lymphoid organs in mice. J Immunol Baltim Md 1950 2013; 190:5313-20; PMID:23589622; doi:10.4049/jimmunol.1202280
22. Hartmann D, Adams JS, Meeker AK, Schneider MA, Lenz BF, Talmadge JE. Dissociation of therapeutic and toxic effects of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethyl cellulose in tumor-bearing mice. Cancer Res 1986; 46:1331-8; PMID:3484679
23. Zobywalski A, Javorovic M, Frankenberger B, Pohla H, Kremmer E, Bigalke I, Schendel DJ. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Transl Med 2007; 5:18; PMID:17430585; doi:10.1186/1479-5876-5-18
24. Aranda F, Llopiz D, Díaz-Valdés N, Riezu-Boj JI, Bezunartea J, Ruiz M, Martínez M, Durantez M, Mansilla C, Prieto J, et al. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res 2011; 71:3214-24; PMID:21402711; doi:10.1158/0008-5472.CAN-10-3259
25. Shojaei H, Oberg H-H, Juricke M, Marischen L, Kunz M, Mundhenke C, Gieseler F, Kabelitz D, Wesch D. Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res 2009; 69:8710-7; PMID:19887600; doi:10.1158/0008-5472.CAN-09-1602
26. Whitmore MM, DeVeer MJ, Edling A, Oates RK, Simons B, Lindner D, Williams BRG. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004; 64:5850-60; PMID:15313929; doi:10.1158/0008-5472.CAN-04-0063
27. Kim Y-G, Park J-H, Reimer T, Baker DP, Kawai T, Kumar H, Akira S, Wobus C, Núñez G. Viral infection augments Nod1/2 signaling to potentiate lethality associated with secondary bacterial infections. Cell Host Microbe 2011; 9:496-507; PMID:21669398; doi:10.1016/j.chom.2011.05.006
28. Krummen M, Balkow S, Shen L, Heinz S, Loquai C, Probst H-C, Grabbe S. Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling, whereas TRIF signaling is indispensable for TLR synergy. J Leukoc Biol 2010; 88:189-99; PMID:20360404; doi:10.1189/jlb.0408228
29. Hartmann D, Schneider MA, Lenz BF, Talmadge JE. Toxicity of polyinosinic-polycytidylic acid admixed with poly-L-lysine and solubilized with carboxymethylcellulose in mice. Pathol Immunopathol Res 1987; 6:37-50; PMID:3447151; doi:10.1159/000157040
30. Krown SE, Kerr D, Stewart WE, Field AK, Oettgen HF. Phase I trials of poly(I,C) complexes in advanced cancer. J Biol Response Mod 1985; 4:640-9; PMID:2418162
31. Lampkin BC, Levine AS, Levy H, Krivit W, Hammond D. Phase II trial of poly(I,C)-LC, an interferon inducer, in the treatment of children with acute leukemia and neuroblastoma:a report from the Children's Cancer Study Group. J Biol Response Mod 1985; 4:531-7; PMID:2416884
32. Stevenson HC, Abrams PG, Schoenberger CS, Smalley RB, Herberman RB, Foon KA. A phase I evaluation of poly(I,C)-LC in cancer patients. J Biol Response Mod 1985; 4:650-5; PMID:2418163
33. Chatterjee S, Crozet L, Damotte D, Iribarren K, Schramm C, Alifano M, Lupo A, Cherfils-Vicini J, Goc J, Katsahian S, et al. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res 2014; 74:5008-18; PMID:25074614; doi:10.1158/0008-5472.CAN-13-2698
34. Cherfils-Vicini J, Platonova S, Gillard M, Laurans L, Validire P, Caliandro R, Magdeleinat P, Mami-Chouaib F, Dieu-Nosjean M-C, Fridman W-H, et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J Clin Invest 2010; 120:1285-97; PMID:20237413; doi:10.1172/JCI36551
35. Salaun B, Coste I, Rissoan M-C, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol Baltim Md 1950 2006; 176:4894-901; PMID:16585585; doi:10.4049/jimmunol.176.8.4894
36. Tormo D, Checińska A, Alonso-Curbelo D, Pérez-Guijarro E, Cañón E, Riveiro-Falkenbach E, Calvo TG, Larribere L, Megías D, Mulero F, et al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 2009; 16:103-14; PMID:19647221; doi:10.1016/j.ccr.2009.07.004
37. Zhao X, Ai M, Guo Y, Zhou X, Wang L, Li X, Yao C. Poly I:C-induced tumor cell apoptosis mediated by pattern-recognition receptors. Cancer Biother Radiopharm 2012; 27:530-4; PMID:23062195; doi:10.1089/cbr.2012.1226
38. Bourquin C, Schmidt L, Lanz A-L, Storch B, Wurzenberger C, Anz D, Sandholzer N, Mocikat R, Berger M, Poeck H, et al. Immunostimulatory RNA oligonucleotides induce an effective antitumoral NK cell response through the TLR7. J Immunol Baltim Md 1950 2009; 183:6078-86; PMID:19890064; doi:10.4049/jimmunol.0901594
39. Bourquin C, Wurzenberger C, Heidegger S, Fuchs S, Anz D, Weigel S, Sandholzer N, Winter G, Coester C, Endres S. Delivery of immunostimulatory RNA oligonucleotides by gelatin nanoparticles triggers an efficient antitumoral response. J Immunother Hagerstown Md 1997 2010; 33:935-44; PMID:20948443; doi:10.1097/CJI.0b013e3181f5dfa7
40. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol Baltim Md 1950 2005; 175:1636-42; PMID:16034103; doi:10.4049/jimmunol.175.3.1636
41. Wang D, Precopio M, Lan T, Yu D, Tang JX, Kandimalla ER, Agrawal S. Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8. Mol Cancer Ther 2010; 9:1788-97; PMID:20515950; doi:10.1158/1535-7163.MCT-09-1198
42. Anz D, Koelzer VH, Moder S, Thaler R, Schwerd T, Lahl K, Sparwasser T, Besch R, Poeck H, Hornung V, et al. Immunostimulatory RNA blocks suppression by regulatory T cells. J Immunol Baltim Md 1950 2010; 184:939-46; PMID:19966212; doi:10.4049/jimmunol.0901245
43. Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res Off J Am Assoc Cancer Res 2011; 17:1765-75; PMID:21233400; doi:10.1158/1078-0432.CCR-10-2672
44. Overwijk WW, Restifo NP. B16 as a mouse model for human melanoma. Curr Protoc Immunol Ed John E Coligan Al 2001; Chapter 20:Unit 20.1; PMID:18432774; doi:10.1002/0471142735.im2001s39
45. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348:69-74; PMID:25838375; doi:10.1126/science.aaa4971